SCHEMBL1684754

SCHEMBL1684754

Cc1ccc2nc(C)c(-c3csc(Nc4ccc(N(C)C)cc4)n3)n2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.62
GAA P10253 8/20 0.62
ALDH1A1 P00352 5/20 0.62
SMN1; SMN2 Q16637 5/20 0.62
KDM4E B2RXH2 5/20 0.62
MEN1 O00255 5/20 0.62
KMT2A Q03164 5/20 0.62
LMNA P02545 4/20 0.62
HTT P42858 4/20 0.62
HPGD P15428 2/20 0.62
ALOX12 P18054 2/20 0.62
NPSR1 Q6W5P4 2/20 0.62
RAB9A P51151 6/20 0.61
TDP1 Q9NUW8 2/20 0.61
L3MBTL1 Q9Y468 2/20 0.61
PRKD3 O94806 1/20 0.55
MAP4K4 O95819 1/20 0.55
PIM1 P11309 1/20 0.55
RPS6KB1 P23443 1/20 0.55
CDK2 P24941 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL18040800 0.99 MAPT (0.64) MAPTGAAALDH1A1SMN1; SMN2KDM4E
SCHEMBL1684691 0.89 MAPT (0.59) MAPTGAAALDH1A1SMN1; SMN2KDM4E
SCHEMBL1684619 0.89 MAPT (0.59) MAPTGAAALDH1A1SMN1; SMN2KDM4E
SCHEMBL2352467 0.89 MAPT (0.59) MAPTGAAALDH1A1SMN1; SMN2KDM4E
Bromide SCHEMBL18040756 0.89 MAPT (0.61) MAPTGAAALDH1A1SMN1; SMN2KDM4E
Bromide SCHEMBL18040698 0.89 MAPT (0.61) MAPTGAAALDH1A1SMN1; SMN2KDM4E
Bromide SCHEMBL18040672 0.89 MAPT (0.61) MAPTGAAALDH1A1SMN1; SMN2KDM4E
SCHEMBL1684894 0.89 GAA (0.59) MAPTGAAALDH1A1SMN1; SMN2KDM4E
Bromide SCHEMBL18040730 0.88 MAPT (0.60) MAPTGAAALDH1A1SMN1; SMN2KDM4E
SCHEMBL1684744 0.87 MAPT (0.64) MAPTGAAALDH1A1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2306836-B1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS INC (US) 2016-09-07 EP claimed
US-8680113-B2 BMI-1 protein expression modulators PTC THERAPEUTICS, INC. (US) 2014-03-25 US claimed
US-20110190239-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS, INC. (US) 2011-08-04 US claimed
EP-2306836-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC Therapeutics, Inc. (US) 2011-04-13 EP claimed
WO-2010002985-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS, INC. (US) 2010-01-07 WO claimed
EP-3111956-B1 BMI 1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS INC (US) 2019-05-08 EP disclosed
EP-3111956-A1 BMI 1 PROTEIN EXPRESSION MODULATORS PTC Therapeutics, Inc. (US) 2017-01-04 EP disclosed
EP-2306836-B1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS INC (US) 2016-09-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190239-A1 BMI-1 PROTEIN EXPRESSION MODULATORS BMI1, CREBBP, BAZ2A MAPT 4026/4885GAA 3522/4885ALDH1A1 2357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.